PETMED EXPRESS INC (PETS): Nasdaq/NYSE listing notice — PetMed Express receives Nasdaq deficiency notice for late FY2025 10-K filing

PETMED EXPRESS INC

Received Nasdaq notice on July 2, 2025 for non-compliance with Listing Rule 5250(c)(1) due to delayed annual report.
Must submit compliance plan by September 1, 2025; Nasdaq may grant exception until December 29, 2025.
Notice has no immediate effect on trading; company previously filed a Form 12b-25 on June 16, 2025.
Company is working to complete financial statements and file Form 10-K as soon as practicable.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PETMED EXPRESS INC received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

July 2, 2025, the Company received an expected notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-K with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. The Notice indicated that the Company must submit a plan to regain compliance with the Listing Rule within 60 calendar days

View on SEC.gov

16 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

PETMED EXPRESS INC filing history →

Source: SEC EDGAR

accession 0001040130-25-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.